Looking for Solutions to the Pitfalls of Developing Novel Antibacterials in an Economically Challenging System

Abstract

The increase in antibacterial resistance (ABR) currently equates in the minds of many with the distant fear that certain antibiotics will not work in 30 years on certain bacteria found in places the majority of us never go to. However, in reality, rising ABR already seriously threatens the effectiveness of compounds with which we treat common bacterial infections, which means that ABR is currently and will continue to undermine the foundations of modern medicine, including surgery and cancer treatment in hospitals, cities and countries across the world. That is why ABR is widely considered a global threat and one of the biggest problems of our current civilization. Conversely, antibiotic developments to market are few. Therefore, in this paper, we have illustrated the barriers to antimicrobial R&D the following questions and provided solutions to effective antimicrobial R&D.

Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections–Overview of Policies Applied in 17 European Countries

“…Adding to these standard pricing and funding policies, additional policies, subsumed as new pricing models or novel payment schemes, have been developed, or are discussed, for some medicines, including vaccines. These developments concern, for instance, one-off treatments in rare diseases (e.g., Advanced Therapy Medicinal Products/ATMPs) and novel antibiotics [ 66 , 67 , 68 ]. Society has an interest (and need) that antibiotics with a lower probability of producing AMR be developed and marketed.…”